We are live on ! Find out more
OTLK icon

Outlook Therapeutics

82 hedge funds and large institutions have $6.16M invested in Outlook Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

0.84% less ownership

Funds ownership: 11.5% → 10.66% (-0.84%)

7% less funds holding

Funds holding: 88 → 82 (-6)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

63% less capital inflows, than outflows

Capital inflows: $2.39M | Capital outflows: $6.41M

Holders
82
Holders Change
-6
Holders Change %
-6.82%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
26
Reduced
19
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q3 2023 in Review

82 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2023, worth a combined $6.16M — down 88% from $51.4M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of OTLK and 13 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 26 added.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $533K. The largest seller was LVW Advisors, exiting entirely with an estimated $3.02M sold.

  • 82 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2023, down from 88 in Q2 2023.
  • Funds reported $6.16M of Outlook Therapeutics stock for Q3 2023, down 88% quarter-over-quarter.
  • 13 funds opened new Outlook Therapeutics positions in Q3 2023 and 18 closed out, a net change of -5 holders.
  • The largest Outlook Therapeutics buyer in Q3 2023 was BNP Paribas Financial Markets, an estimated $533K added.
  • The largest Outlook Therapeutics seller in Q3 2023 was LVW Advisors, an estimated $3.02M sold.

Based on aggregated 13F filings for Q3 2023.